Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.720
-0.110 (-6.01%)
At close: Aug 13, 2025, 4:00 PM
1.760
+0.040 (2.33%)
Pre-market: Aug 14, 2025, 8:00 AM EDT
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,361,917
Market Cap
92.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
QNCX News
- 2 days ago - Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Business Wire
- 7 days ago - Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP - Business Wire
- 4 weeks ago - Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Business Wire
- 4 weeks ago - Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board - Business Wire
- 7 weeks ago - Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference - Business Wire
- 2 months ago - Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities - Business Wire
- 2 months ago - Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities - Business Wire
- 2 months ago - Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Business Wire